|
Journal of Zhejiang University SCIENCE A
ISSN 1673-565X(Print), 1862-1775(Online), Monthly
2022 Vol.23 No.12 P.955-973
Inkjet 3D bioprinting for tissue engineering and pharmaceutics
Abstract: 3D bioprinting has the capability to create 3D cellular constructs with the desired shape using a layer-by-layer approach. Inkjet 3D bioprinting, as a key component of 3D bioprinting, relies on the deposition of cell-laden droplets to create native-like tissues/organs which are envisioned to be transplantable into human body for replacing damaged ones. Benefiting from its superiorities such as high printing resolution and deposition accuracy, inkjet 3D bioprinting has been widely applied to various areas, including, but not limited to, tissue engineering and drug screening in pharmaceutics. Even though inkjet 3D bioprinting has proved its feasibility and versatility in various fields, the current applications of inkjet 3D bioprinting are still limited by the printing technique and material selection. This review, which specifically focuses on inkjet 3D bioprinting, firstly summarizes the techniques, materials, and applications of inkjet 3D bioprinting in tissue engineering and drug screening, subsequently discusses the major challenges that inkjet 3D bioprinting is facing, and lastly summarizes potential solutions to those challenges.
Key words: Inkjet 3D bioprinting; Biomaterials; In vitro tissue models; In vivo tissue substitutes; Drug screening
机构:1浙江大学,流体动力与机电系统国家重点实验室,中国杭州,310058;2浙江大学,浙江省三维打印工艺与装备重点实验室,中国杭州,310058;3这些作者对本文的贡献相同
概要:生物3D打印具有通过层层叠加增材制造的方式构建所需载活细胞3D结构的能力。作为生物3D打印技术的重要组成部分,喷墨生物3D打印利用载细胞液滴作为基本单元,构造仿生组织或器官,以期用于替代人体损伤或病变的组织或器官。由于其优异的打印精度和准确性,喷墨生物3D打印目前已被广泛应用于组织工程和药物研发等领域。然而,尽管大量的应用已证明其在不同领域内的可行性和广泛适用性,喷墨生物3D打印仍然受限于生物材料的选择和打印工艺。本文针对喷墨生物3D打印,首先归纳总结了现有关键打印技术、可打印生物材料和其在组织工程和药学领域内的典型应用,进而对其面临的关键挑战和潜在解决方案进行讨论。
关键词组:
References:
Open peer comments: Debate/Discuss/Question/Opinion
<1>
DOI:
10.1631/jzus.A2200569
CLC number:
Download Full Text:
Downloaded:
3625
Download summary:
<Click Here>Downloaded:
2639Clicked:
31705
Cited:
0
On-line Access:
2024-08-27
Received:
2023-10-17
Revision Accepted:
2024-05-08
Crosschecked:
2023-01-13